Operational Aspects of Terminating the Doxazosin Arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

MLA

Pressel, S. L., et al. “Operational Aspects of Terminating the Doxazosin Arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).” Controlled Clinical Trials, vol. 22, no. 1, Jan. 2001, pp. 29–41. EBSCOhost, https://doi.org/10.1016/S0197-2456(00)00109-4.

APA

Pressel, S. L., Davis, B. R., Jr., J. T. W., Geraci, T. S., Kingry, C., Ford, C. E., Piller, L. B., Bettencourt, J., Kimmel, B., & Lusk, C. (2001). Operational Aspects of Terminating the Doxazosin Arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Controlled Clinical Trials, 22(1), 29–41. https://doi.org/10.1016/S0197-2456(00)00109-4

Chicago

Pressel, S. L., B. R. Davis, J. T. Wright Jr., T. S. Geraci, C. Kingry, C. E. Ford, L. B. Piller, J. Bettencourt, B. Kimmel, and C. Lusk. 2001. “Operational Aspects of Terminating the Doxazosin Arm of the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).” Controlled Clinical Trials 22 (1): 29–41. doi:10.1016/S0197-2456(00)00109-4.